Drug Formulary Committee (DFC)
DFC plays a key role in the management of the HA Drug Formulary and in the revision of the existing drug list.
Terms of Reference
The Terms of Reference of DFC are:
a)
To manage and review the HA Drug Formulary which serves as a standard and reference for all HA institutions;
b)
To conduct biennial comprehensive review of the HA Drug Formulary or upon request of DMC;
c)
To make recommendations for management and operation of the HA Drug Formulary to DMC; and
d)
To advise DMC on the number of expert panels required for operation of the HA Drug Formulary.
Composition
The DFC Chairman would be elected among the DTC Chairmen of all seven clusters for a term of 2 years, usually prior to the biennial comprehensive review of the HA Drug Formulary. Their tenure can be renewed upon consensus among the Cluster DTC Chairmen. The DFC composition facilitates making of rational and balanced decisions to cater for the service needs of different clusters. DFC may co-opt additional members from the Expert Panels when necessary. The DFC composition is as follows:
a)
Corporate Director overseeing pharmaceutical service management;
b)
The remaining six chairmen of Cluster DTC; and
c)
Chief Pharmacist.
All DFC members are positional appointments.